GnRH Receptor Antagonist

GnRH Receptor Antagonists (32):

Cat. No.	Product Name	Effect	Purity

HY-16168A

Degarelix	Antagonist	99.92%
Degarelix is a competitive and reversible gonadotropin-releasing hormone receptor (GnRHR/LHRHR) antagonist. Degarelix can be used for prostate cancer research.

HY-P0009A

Cetrorelix Acetate	Antagonist	99.87%
Cetrorelix Acetate (SB-75 acetate) is a potent gonadotropin-releasing hormone (GnRH) receptor antagonist with an IC₅₀ of 1.21 nM.

HY-16474

Relugolix	Antagonist	99.95%
Relugolix (TAK-385) is a potent, orally active, nonpeptidic gonadotropin-releasing hormone (GnRH) antagonist. Relugolix possesses high affinity and potent antagonistic activity for human receptor (binding IC₅₀=0.33 nM) and monkey receptor (IC₅₀=0.32 nM) compared with TAK-013 (HY-100209). Relugolix is used for the study of sex-hormone-dependent diseases, such as including endometriosis, uterine fibroids and prostate cancer et al.

HY-P2357

MI-1544	Antagonist
MI-1544 is a powerful GnRH antagonist. MI-1544 induces inhibitory effects on the pituitary LH release and on gonads. MI-1544 can be used for the research of antifertility effect.

HY-P2028

BIM 21009	Antagonist
BIM 21009 is a LHRH and GnRH receptor antagonist. BIM 21009 inhibits tumor growth.

HY-14369

Elagolix sodium	Antagonist	99.94%
Elagolix sodium is a human GnRH receptor (GnRHR) antagonist with an IC₅₀ and K_i of 0.25 and 3.7 nM, respectively.

HY-14789

(R)-Elagolix	Antagonist
Elagolix is a highly potent, selective, orally-active, short-duration, non-peptide antagonist of the gonadotropin-releasing hormone receptor (GnRHR) (KD = 54 pM).

HY-13534A

Abarelix Acetate	Antagonist	99.90%
Abarelix Acetate (PPI 149 Acetate; R 3827 Acetate) is a potent gonadotrophin-releasing hormone (GnRH) antagonist, used for prostate cancer research.

HY-P0013

Antide	Antagonist	99.86%
Antide (D-21074) is a potent LHRH antagonist. Antide also can be used for the research of prostatic cancer.

HY-16027A

Acyline TFA	Antagonist	99.87%
Acyline TFA, a GnRH peptide analogue, is a GnRH antagonist that inhibits gonadotropin and testosterone (T) levels.

HY-134864

GnRH antagonist 2	Antagonist	98.16%
GnRH antagonist 2 (formula I) is a GnRH receptor antagonist that can be used for endometriosis research.

HY-P0009

Cetrorelix	Antagonist
Cetrorelix is a potent gonadotrophin-releasing hormone (GnRH) antagonist. Cetrorelix inhibits the endogenous luteinizing hormone surge during ovarian stimulation. Cetrorelix reduces cyclophosphamide induced ovarian follicular destruction in mice.

HY-13534

Abarelix	Antagonist	99.90%
Abarelix (R3827; PPI 149) is a potent gonadotrophin-releasing hormone (GnRH) antagonist, used for prostate cancer treatment.

HY-13699

NBI-42902	Antagonist	98.65%
NBI-42902 is an orally active, potent functional and competitive antagonist of GnRH receptor with an IC₅₀ value of 0.79 nM, a K_i value of 0.56 nM, respectively. NBI-42902 inhibits GnRH-stimulated inositol phosphate (IP) accumulation, Ca²⁺ flux, and ERK1/2 activation. NBI-42902 inhibits serum luteinizing hormone (LH) in castrated male macaques. NBI-42902 can be used for research on sex-hormone-related diseases.

HY-109532

Ganirelix acetate	Antagonist	98.03%
Ganirelix acetate (Ganirest) is an injectable competitive gonadotropin-releasing hormone (GnRH) antagonist. Ganirelix acetate directly competes against the endogenous molecule for receptor binding, and causes a rapid reduction in estradiol levels. Ganirelix acetate can be used for researching ovarian hyperstimulation syndrome (OHSS).

HY-144863

BAY 1214784	Antagonist
BAY 1214784 is a potent, selective, and orally active antagonist of the human gonadotropin-releasing hormone receptor (hGnRH-R). BAY 1214784 is a spiroindoline derivative compound. BAY 1214784 effectively lowers plasma luteinizing hormone levels by up to 49%, at the same time being associated with low pharmacokinetic variability and good tolerability. BAY 1214784 has the potential for the research of uterine fibroids.

HY-151247

GnRH-R antagonist 1	Antagonist
GnRH-R antagonist 1 (compound 21a) is an orally safe and membrane-permeable GnRH-R antagonist with high binding affinity (IC₅₀=0.57 nM) and potent in vitro antagonistic activity (IC₅₀=2.18 nM). GnRH-R antagonist 1 can be used in studies of advanced prostate cancer and premature LH peaks preventing.

HY-109093

Linzagolix	Antagonist	99.81%
Linzagolix (KLH-2109; OBE-2109) is a potent, non-peptide, and orally active GnRH antagonist. Linzagolix can be used for uterine fibroids, endometriosis, adenomyosis research.

HY-152856

Merigolix	Antagonist
Merigolix is a potent gonadotrophin releasing hormone (GnRH) antagonist.

HY-16168B

Degarelix acetate hydrate	Antagonist
Degarelix acetate hydrate is a competitive and reversible gonadotropin-releasing hormone receptor (GnRHR/LHRHR) antagonist. Degarelix acetate hydrate can be used for prostate cancer research.

Name
Email *

	Sorry, but the email address you supplied was invalid.